Primary intestinal lymphangiectasia in an elderly female patient: A case report on a rare cause of secondary immunodeficiency.

Protein loss via the gut can be caused by a number of gastrointestinal disorders, among which intestinal lymphangiectasia has been described to not only lead to a loss of proteins but also to a loss of lymphocytes, resembling secondary immunodeficiency. We are reporting on a 75-year-old female patient who came to our hospital because of a minor stroke. She had no history of serious infections.

GM-CSF Production by Tumor Cells Is Associated with Improved Survival in Colorectal Cancer.

Purpose: Colorectal cancer infiltration by CD16(+) myeloid cells correlates with improved prognosis. We addressed mechanistic clues and gene and protein expression of cytokines potentially associated with macrophage polarization.

Experimental Design: GM-CSF or M-CSF-stimulated peripheral blood CD14(+) cells from healthy donors were cocultured with colorectal cancer cells.

When a colonoscopy becomes a duodenoscopy: a palliative treatment of a malignant sigmoidoduodenal fistula.

We report a case of a 63-year-old female patient suffering from cachexy, anaemia and intractable chronic diarrhoea. As an underlying disease, we found a malignant sigmoidoduodenal fistula of a primary adenocarcinoma of the sigma which represents a rare complication of a frequent disease. Despite the theoretical need for a pancreaticoduodenectomy, only a multivisceral en-bloc resection of the small intestine and left adnexa was performed because of bad general and nutritional condition; this case illustrates a successful multimodal treatment with a palliative intention of a locally advanced colon cancer to alleviate clinical symptoms.

Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.

Background: Programmed cell death 1 (PD-1) receptor triggering by PD ligand 1 (PD-L1) inhibits T cell activation. PD-L1 expression was detected in different malignancies and associated with poor prognosis. Therapeutic antibodies inhibiting PD-1/PD-L1 interaction have been developed.